CliffBio
biologic

Granix

tbo-filgrastim

Loss of exclusivityJuly 2030projected — 12-year biologic exclusivity estimate
CompanyUAB Teva Baltics

Drug detail

Brand nameGranix
Active ingredienttbo-filgrastim
Strength300MCG/1ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2018
Marketing statusRx

More from UAB Teva Baltics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Granix patent cliff — loss of exclusivity July 2030 | CliffBio